Skip to content

Clinical evaluation of in-office Bleaching Agents

Evaluation of different In-office Bleaching Agents: a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-10cg75rw
Enrollment
Unknown
Registered
2024-03-25
Start date
2023-08-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleaching Agents

Interventions

This is a double-blind, two-arm, randomized controlled clinical trial. Experimental group: 22 participants with discolored teeth, A3 shade or darker according to the Vita Classical shade guide, will r
SP5.312.109.198.455.187

Sponsors

Universidade Federal de Santa Maria
Lead Sponsor
Universidade Federal de Santa Maria
Collaborator

Eligibility

Age
No minimum to 35 Years

Inclusion criteria

Inclusion criteria: Have at least 24 teeth in the mouth. Be interested and available for treatment. Good periodontal health, without the need for interventions. Good general health. Dental elements color A3 or darker according to the Vita Classical shade guide. Caries-free teeth.Teeth without restorative needs

Exclusion criteria

Exclusion criteria: Patients who refuse to participate in the treatment. Pregnant women. Nursing mothers. Smokers. Patients with bruxism or another condition that causes gingival recession and/or dentine exposure. Patients who have already undergone dental bleaching. Patients who report spontaneous sensitivity and/or sensitivity generated by cold drinks and foods. Patients undergoing orthodontic treatment. Patients undergoing periodontal treatment. Patients with ISG >30% of the areas/sites involved. Patients with IPV >30% of the areas/sites involved. Anterior teeth with restoration on the buccal surface. Anterior teeth with veneers or crowns.Teeth with internal staining (tetracycline, fluorosis or endodontic treatment). Endodontically treated anterior teeth.· Patients being treated with anti-inflammatories and/or analgésico

Design outcomes

Primary

MeasureTime frame
Expected Outcome 1: Evaluate the color difference between the pre and post-intervention periods verified by measurements with a clinical spectrophotometer and color difference calculation. The color difference will be evaluated and interpreted by the visual acceptability and perceptability thresholds. It is expected to find a mean color difference above 5.4 deltaE units for both treatments, corresponding with excellent whitening outcome according with the acceptability and perceptability thresholds.;Outcome Found 1: An average color difference of 3.38 and 4.48 deltaE 2000 units was observed for the groups treated with 37% carbamide peroxide and 35% hydrogen peroxide, respectively, verified through measurements with a clinical spectrophotometer and calculations of color difference between the pre- and post-intervention periods. The color difference found between the evaluation periods corresponded to good and very good results according to the acceptability and visual perceptibility parameters.

Secondary

MeasureTime frame
Secondary outcomes were not expected.

Countries

Brazil

Contacts

Public ContactLetícia Durand

Universidade Federal de Santa Maria

leticia.durand@ufsm.br+55(055)98117080

Outcome results

None listed

Source: REBEC (via WHO ICTRP)